Phenylketonuria (PKU) Market Report 2026

The phenylketonuria (pku) market size has grown strongly in recent years. It will grow from $0.93 billion in 2025 to $1.01 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to improved awareness of rare metabolic disorders, expansion of newborn screening initiatives, availability of dietary-based treatment options, increased diagnosis rates of PKU, early clinical research into enzyme therapies.

The phenylketonuria (pku) market size is expected to see strong growth in the next few years. It will grow to $1.4 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to growing pipeline of gene therapies, increasing adoption of precision medicine approaches, rising investments in rare disease research, expansion of home-based management solutions, growing demand for long-term disease control therapies. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, rising focus on gene therapy development, growing demand for personalized dietary management solutions, expansion of newborn screening programs, enhanced integration of digital patient monitoring tools.

The increasing incidence of genetic disorders is expected to drive the growth of the phenylketonuria (PKU) market in the coming years. Genetic disorders are medical conditions that arise from abnormalities in an individual’s DNA, including gene or chromosomal mutations, deletions, or duplications. The rising number of genetic disorder cases is linked to factors such as higher maternal age, environmental influences, advancements in diagnostic technologies, and increased awareness, all of which have improved detection rates. Phenylketonuria plays an important role in illustrating how inherited enzyme deficiencies can result in serious metabolic complications. For instance, in March 2024, according to Gene People, a UK-based registered charity, genetic conditions affect approximately 1 in 25 children, impacting more than 2.4 million children and adults in the UK. In addition, nearly 30,000 newborns and children in the UK are diagnosed with a genetic condition each year. Therefore, the rising number of genetic disorders is contributing to the growth of the phenylketonuria (PKU) market.

Major companies operating in the phenylketonuria (PKU) market are concentrating on the development of innovative treatments such as oral therapies that help lower blood phenylalanine (Phe) levels and prevent toxic accumulation associated with PKU. Oral therapy refers to treatment administered by mouth, where the medication is swallowed and absorbed through the digestive system. For example, in July 2025, PTC Therapeutics, a US-based biopharmaceutical company, received approval from the Food and Drug Administration for Sephience (sepiapterin), an oral therapy for children and adults with sepiapterin-responsive PKU or hyperphenylalaninemia. This therapy improves phenylalanine metabolism by enhancing the activity of the deficient phenylalanine hydroxylase enzyme through increased tetrahydrobiopterin levels, thereby reducing blood phenylalanine concentrations. Sephience is intended for use alongside a phenylalanine-restricted diet, offering a targeted and convenient option for long-term PKU management in responsive patients.

In August 2024, Otsuka Holdings Co. Ltd., a Japan-based pharmaceutical company, acquired Jnana Therapeutics Inc. for approximately $1.1 billion. Through this acquisition, Otsuka Pharmaceutical gained access to JNT-517, an oral drug candidate for the treatment of the rare genetic disorder phenylketonuria, while also strengthening its pipeline of innovative therapies for autoimmune diseases. Jnana Therapeutics Inc. is a US-based biotechnology company focused on developing treatments for phenylketonuria.

Major companies operating in the phenylketonuria (pku) market are Abbott Laboratories, Merck KGaA, Agios Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Nutricia International Private Limited, Codexis Inc., Eton Pharmaceuticals Inc., Vitaflo International Ltd., American Gene Technologies International Inc., Cambrooke Therapeutics Inc., Generation Bio Co., Mead Johnson & Company LLC, Synlogic Inc., Homology Medicines Inc., Aeglea BioTherapeutics Inc., MetaX Biosciences Ltd., SOM Biotech SL, Applied Molecular Transport Inc., Codexis Genomics, Bluebird Bio Inc., Alnylam Pharmaceuticals Inc.

North America was the largest region in the phenylketonuria (PKU) market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the phenylketonuria (pku) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the phenylketonuria (pku) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the phenylketonuria market by increasing costs of imported pharmaceutical ingredients, enzyme formulations, diagnostic reagents, and specialized medical nutrition products used in PKU management. Treatment providers and specialty clinics in North America and Europe are most affected due to reliance on cross-border sourcing of rare-disease therapies, while Asia-Pacific faces higher costs for imported diagnostic technologies. These tariffs are contributing to higher treatment expenses and reimbursement pressures. However, they are also encouraging local manufacturing of medical nutrition products, regional drug formulation capabilities, and increased investment in domestic rare-disease therapy development.

The phenylketonuria (pku) market research report is one of a series of new reports that provides phenylketonuria (pku) market statistics, including phenylketonuria (pku) industry global market size, regional shares, competitors with a phenylketonuria (pku) market share, detailed phenylketonuria (pku) market segments, market trends and opportunities, and any further data you may need to thrive in the phenylketonuria (pku) industry. This phenylketonuria (pku) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Phenylketonuria (PKU) is a rare inherited metabolic condition in which the body is unable to properly metabolize an amino acid known as phenylalanine (Phe), which is present in many protein-rich foods. This metabolic impairment occurs due to a deficiency or dysfunction of the phenylalanine hydroxylase (PAH) enzyme, which is responsible for converting phenylalanine into another amino acid, tyrosine.

The primary types of phenylketonuria in the PKU market include hyperphenylalaninemia (HPA), mild phenylketonuria, moderate and variant PKU, and classic phenylketonuria. Hyperphenylalaninemia (HPA) is a genetic metabolic disorder caused by insufficient activity of the phenylalanine hydroxylase enzyme, resulting in elevated levels of phenylalanine in the blood. Treatment options for PKU include enzyme replacement therapy, gene therapy, medications, and dietary management. Diagnostic approaches involve genetic testing, biochemical analysis, and newborn screening programs. The main end users of PKU diagnostics and treatments include specialty clinics, research institutes, home healthcare providers, and hospitals.

The phenylketonuria (PKU) market consists of revenues earned by entities by provide services such as enzyme therapy, screening tests, PKU tests, and PKU formula. The market value includes the value of related goods sold by the service provider or included within the service offering. The phenylketonuria (PKU) market also includes sales of sapropterin (Kuvan), pegvaliase-pqpz (Palynziq) and dietary supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.